Healthcare

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.

Biopolymer material decontamination company Karamedica and genomic sequencing provider Murrieta Genomics have both joined UC Riverside's newly-launched Life Sciences Incubator.

IP Group portfolio company Hinge Health has pushed its valuation to $3bn following a $300m series D round co-led by Coatue Management and Tiger Global.

The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.